illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. AADI Bioscience
Company logo

AADI Bioscience | Sustainability Performance

https://www.aadibio.com/
Linkedin

Conducts research and development in targeted therapeutics with a focus on oncology and rare diseases. Works on investigational treatments supported by clinical trials. Collaborates with partners and medical institutions to advance drug candidates through regulatory and commercialization pathways.

2011

United States

11 - 50 employees

Biotechnology

$1M - 10M in revenue

N/A in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6290
Overall
#1396
in United States
#122
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Envista

United States, Hospital & Health Care, Medical Device


Company logo
Encompass health

United States, Hospital & Health Care, Hospital & Health Care


Company logo
Cigna Healthcare

United States, Hospital & Health Care, Hospital & Health Care

Market cap

195.0M $, 2026▲52.3% YoY

Revenue

7.0M $, 2025▼257.1% YoY

R&D intensity

1285.71% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

195.0M $, 2026▲52.3% YoY

Revenue

7.0M $, FY2025▼257.1% YoY

EBITDA

-114.0M $, FY2025▼9.1% YoY

Operating margin

-1601% Industry: -370▲83.8% YoY

Revenue & EBITDA

$7.0MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-61.2M 2024▼4% YoY

Capex

1.0M 2024▼200% YoY

R&D intensity

1.3K%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

-15.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.0

▼ 2.5%

2023

0.0

▼ 5.4%

2024

0.0

▼ 1.9%

2025

0.0

2030

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

58%
Independent Directors

7 out of 12 incl. management

Powered by illuminem

Overall score

34

Environment

39

Social

15

Governance

49

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email